Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice
Varun Pathak, Srividya Vasu, Victor A. Gault, et al.
Diabetologia (2015) Vol. 58, Iss. 9, pp. 2144-2153
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
Kimberley El, Jonathan D. Douros, Francis S. Willard, et al.
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 945-954
Open Access | Times Cited: 66
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 5, pp. 587-597
Open Access | Times Cited: 31
N‐terminally and C‐terminally truncated forms of glucose‐dependent insulinotropic polypeptide are high‐affinity competitive antagonists of the human GIP receptor
L. Hansen, Alexander H. Sparre‐Ulrich, Mikkel Christensen, et al.
British Journal of Pharmacology (2015) Vol. 173, Iss. 5, pp. 826-838
Open Access | Times Cited: 90
Islet distribution of Peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human beta-cell function and survival
Dawood Khan, Srividya Vasu, R. Charlotte Moffett, et al.
Molecular and Cellular Endocrinology (2016) Vol. 436, pp. 102-113
Open Access | Times Cited: 74
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Lærke S. Gasbjerg, M Gabe, Bolette Hartmann, et al.
Peptides (2018) Vol. 100, pp. 173-181
Closed Access | Times Cited: 73
New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders
Nigel Irwin
World Journal of Diabetes (2015) Vol. 6, Iss. 15, pp. 1285-1285
Open Access | Times Cited: 57
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
Bin Yang, Vasily M. Gelfanov, Kimberley El, et al.
Molecular Metabolism (2022) Vol. 66, pp. 101638-101638
Open Access | Times Cited: 27
Influence of neuropeptide Y and pancreatic polypeptide on islet function and beta-cell survival
Dawood Khan, Srividya Vasu, R. Charlotte Moffett, et al.
Biochimica et Biophysica Acta (BBA) - General Subjects (2017) Vol. 1861, Iss. 4, pp. 749-758
Open Access | Times Cited: 45
Tetrahydrocurcumin ameliorates diabetes profiles of db/db mice by altering the composition of gut microbiota and up-regulating the expression of GLP-1 in the pancreas
Tianmin Yuan, Zhujun Yin, Zhixiang Yan, et al.
Fitoterapia (2020) Vol. 146, pp. 104665-104665
Open Access | Times Cited: 39
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
John Wilding, Surya Panicker Rajeev, Ralph A. DeFronzo
Diabetes Care (2016) Vol. 39, Iss. Supplement_2, pp. S154-S164
Open Access | Times Cited: 38
The Pancreatic ß-cell Response to Secretory Demands and Adaption to Stress
Michael A. Kalwat, Donalyn Scheuner, Karina Rodrigues dos Santos, et al.
Endocrinology (2021) Vol. 162, Iss. 11
Open Access | Times Cited: 26
Obesity-driven hunger: From pathophysiology to intervention
Ahmad Khusairi Azemi, Yahkub Babatunde Mutalub, Monsurat Abdulwahab, et al.
Obesity Medicine (2025), pp. 100588-100588
Closed Access
Development of a long-acting unbiased GIP receptor agonist for studies of GIP’s role in bone metabolism
Esther Karen Tordrup, Sarina Gadgaard, Johanne Agerlin Windeløv, et al.
Biochemical Pharmacology (2025), pp. 116893-116893
Closed Access
A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice
Annie Hasib, Ming T. Ng, Dawood Khan, et al.
Peptides (2018) Vol. 100, pp. 202-211
Closed Access | Times Cited: 31
An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice
Annie Hasib, Ming T. Ng, Victor A. Gault, et al.
Diabetologia (2016) Vol. 60, Iss. 3, pp. 541-552
Open Access | Times Cited: 30
Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes
Anand-Krishna Singh, Rameshwar Jatwa, A. N. Purohit, et al.
Journal of Asian Natural Products Research (2017) Vol. 19, Iss. 10, pp. 1036-1045
Closed Access | Times Cited: 26
Effects of 2 Novel PYY(1-36) Analogues, (P3L31P34)PYY(1-36) and PYY(1-36)(Lys12PAL), on Pancreatic Beta-Cell Function, Growth, and Survival
Ryan A. Lafferty, Victor A. Gault, Peter R. Flatt, et al.
Clinical Medicine Insights Endocrinology and Diabetes (2019) Vol. 12
Open Access | Times Cited: 25
Peptide YY (1–36) peptides from phylogenetically ancient fish targeting mammalian neuropeptide Y1 receptors demonstrate potent effects on pancreatic β‐cell function, growth and survival
Ryan A. Lafferty, Neil Tanday, Andrew McCloskey, et al.
Diabetes Obesity and Metabolism (2019) Vol. 22, Iss. 3, pp. 404-416
Open Access | Times Cited: 23
C-terminal degradation of PYY peptides in plasma abolishes effects on satiety and beta-cell function
Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
Biochemical Pharmacology (2018) Vol. 158, pp. 95-102
Open Access | Times Cited: 22
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt
Peptides (2024) Vol. 174, pp. 171168-171168
Closed Access | Times Cited: 2
Does GIPR blockade as well as agonism have a role to play in management of obesity and diabetes?
Ryan A. Lafferty, Peter R. Flatt, Victor A. Gault, et al.
Journal of Endocrinology (2024) Vol. 262, Iss. 2
Open Access | Times Cited: 2
Expression of Gastrin Family Peptides in Pancreatic Islets and Their Role in β-Cell Function and Survival
Dawood Khan, Srividya Vasu, R. Charlotte Moffett, et al.
Pancreas (2018) Vol. 47, Iss. 2, pp. 190-199
Closed Access | Times Cited: 20
Anti-diabetic actions of esculentin-2CHa(1–30) and its stable analogues in a diet-induced model of obesity-diabetes
Srividya Vasu, Opeolu O. Ojo, R. Charlotte Moffett, et al.
Amino Acids (2017) Vol. 49, Iss. 10, pp. 1705-1717
Closed Access | Times Cited: 19
Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists
Neil Tanday, Ryan A. Lafferty, Peter R. Flatt, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 12, pp. 2353-2363
Open Access | Times Cited: 11
Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln
Annie Hasib, Ming T. Ng, Dawood Khan, et al.
European Journal of Pharmacology (2018) Vol. 834, pp. 126-135
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top